Copies of extracts of Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2025 in Financial Express (English Newspaper) all editions and Nava ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zenotech Laboratories has published its audited standalone financial results for Q4 FY25 and full year FY25 in the Financial Express (English) and Nava Telangana (Telugu) newspapers on April 27, 2025, as required under SEBI Regulation 47. For Q4 FY25, total income rose to ₹1,262.41 lakhs (vs ₹943.35 lakhs in Q4 FY24), while net profit after tax stood at ₹122.98 lakhs (vs ₹60.61 lakhs in Q4 FY24) despite an exceptional loss of ₹4.88 lakhs; quarterly EPS was ₹0.20. For the full year FY25, total income was ₹4,459.57 lakhs (vs ₹4,183.72 lakhs in FY24), but net profit fell to ₹561.29 lakhs from ₹827.15 lakhs, pulled down by exceptional items of ₹192.32 lakhs. Full-year EPS declined to ₹0.92 from ₹1.36, while reserves strengthened to ₹3,510.02 lakhs from ₹2,951.10 lakhs.
The Q4 shows a healthy YoY rebound in both revenue and profit, but the full-year picture is weaker due to large exceptional charges. Shareholders should note the ~32% drop in annual net profit and EPS decline even as the topline grew modestly — the stock may see limited positive reaction given the mixed annual performance.